Viking Therapeutics Q1 Viewed as Supporting Maintenance Profile, Oppenheimer Says

MT Newswires Live05-01

Viking Therapeutics (VKTX) increased focus on maintenance dosing in its obesity program, with additional maintenance arms expected to further refine long-term dosing of VK2735, Oppenheimer said.

The company added four additional subcutaneous maintenance arms, bringing the total to eight, which are expected to inform dosing decisions for its Vanquish extension studies and ongoing maintenance evaluation.

Oppenheimer said in a Wednesday note that it expects data from the subcutaneous maintenance program in 3Q26, with flat weight loss outcomes viewed as a positive result. The brokerage said the company's approach to maintenance is differentiated from competitors and aligned with its healthy aging thesis.

The investment firm also said insights from new CCO Neil Aubuchon are helping refine VK2735's development strategy and overall product positioning.

Oppenheimer has an outperform rating on the stock with a price target of $100.

Shares of Viking were down 4.1% in Thursday trading.

Price: 30.02, Change: -1.31, Percent Change: -4.18

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2632506126?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-01 01:34","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2632506126","market":"sh","top_or_hot":-1,"title":"Viking Therapeutics Q1 Viewed as Supporting Maintenance Profile, Oppenheimer Says","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/VKTX\">Viking</a> <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (VKTX) increased focus on maintenance dosing in its obesity program, with additional maintenance arms expected to further refine long-term dosing of VK2735, Oppenheimer said.</p><p>The company added four additional subcutaneous maintenance arms, bringing the total to eight, which are expected to inform dosing decisions for its Vanquish extension studies and ongoing maintenance evaluation.</p><p>Oppenheimer said in a Wednesday note that it expects data from the subcutaneous maintenance program in 3Q26, with flat weight loss outcomes viewed as a positive result. The brokerage said the company's approach to maintenance is differentiated from competitors and aligned with its healthy aging thesis.</p><p>The investment firm also said insights from new CCO Neil Aubuchon are helping refine VK2735's development strategy and overall product positioning.</p><p>Oppenheimer has an outperform rating on the stock with a price target of $100.</p><p>Shares of Viking were down 4.1% in Thursday trading.</p><p>Price: 30.02, Change: -1.31, Percent Change: -4.18</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Viking Therapeutics Q1 Viewed as Supporting Maintenance Profile, Oppenheimer Says</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nViking Therapeutics Q1 Viewed as Supporting Maintenance Profile, Oppenheimer Says\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-05-01 01:34</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/VKTX\">Viking</a> <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (VKTX) increased focus on maintenance dosing in its obesity program, with additional maintenance arms expected to further refine long-term dosing of VK2735, Oppenheimer said.</p><p>The company added four additional subcutaneous maintenance arms, bringing the total to eight, which are expected to inform dosing decisions for its Vanquish extension studies and ongoing maintenance evaluation.</p><p>Oppenheimer said in a Wednesday note that it expects data from the subcutaneous maintenance program in 3Q26, with flat weight loss outcomes viewed as a positive result. The brokerage said the company's approach to maintenance is differentiated from competitors and aligned with its healthy aging thesis.</p><p>The investment firm also said insights from new CCO Neil Aubuchon are helping refine VK2735's development strategy and overall product positioning.</p><p>Oppenheimer has an outperform rating on the stock with a price target of $100.</p><p>Shares of Viking were down 4.1% in Thursday trading.</p><p>Price: 30.02, Change: -1.31, Percent Change: -4.18</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"OPY","symbol_name":"奥本海默控股","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2632506126","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2632506126","pubTimestamp":1777570466,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Viking Therapeutics (VKTX) increased focus on maintenance dosing in its obesity program, with additional maintenance arms expected to further refine long-term dosing of VK2735, Oppenheimer said.The co","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"OPY":"奥本海默控股","BK4599":"减肥药","VKTX":"Viking Therapeutics, Inc.","BK4588":"碎股","BK4585":"ETF&股票定投概念","BK4139":"生物科技","BK4127":"投资银行业与经纪业"},"translate_title":"奥本海默表示，Viking Therapeutics第一季度被视为支持维护状况","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VKTX":1.5,"OPY":1.5},"content_text":"Viking Therapeutics (VKTX) increased focus on maintenance dosing in its obesity program, with additional maintenance arms expected to further refine long-term dosing of VK2735, Oppenheimer said.The company added four additional subcutaneous maintenance arms, bringing the total to eight, which are expected to inform dosing decisions for its Vanquish extension studies and ongoing maintenance evaluation.Oppenheimer said in a Wednesday note that it expects data from the subcutaneous maintenance program in 3Q26, with flat weight loss outcomes viewed as a positive result. The brokerage said the company's approach to maintenance is differentiated from competitors and aligned with its healthy aging thesis.The investment firm also said insights from new CCO Neil Aubuchon are helping refine VK2735's development strategy and overall product positioning.Oppenheimer has an outperform rating on the stock with a price target of $100.Shares of Viking were down 4.1% in Thursday trading.Price: 30.02, Change: -1.31, Percent Change: -4.18","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2632506126","isCrawlerRequest":true}